Keywords: AML; inv(16); CBF␤/MYH11; MRD; BMT
geneic BMT or PBPCT was studied by PCR of minisatellite one busulfan (4 mg/kg/day for 4 days), thiotepa (5 mg/kg/day for 2 days) and cyclophosphamide (60 gene regions (VNTR-PCR).
mg/kg/day × 2). All transplants were performed without prior ex vivo removal of donor lymphocytes from the graft. Irradiated leukocyte-depleted blood products were used Materials and methods exclusively for blood component substitution throughout the post-transplant course.
Patients
Prophylaxis of acute GVHD of patients treated by alloTen patients with inv(16) leukemia who underwent allogeneic transplantation consisted of short-course methotrexgeneic transplantation with bone marrow (n = 5) or periphate and cyclosporin A (CsA) in five patients, of CsA alone eral blood progenitor cells (n = 3), or autologous BMT (n in three patients, as shown in Table 1 . = 2) at our institution were studied (Table 1) . Six patients were diagnosed with de novo FAB M4Eo, and four patients were diagnosed with AML M4. The median age at diagMorphologic and cytogenetics nosis was 31 years (range 17-40). Seven patients were male and three female.
AML was diagnosed according to standard FAB morphoPatients were transplanted in first remission (1CR, eight logic and cytochemical criteria. 9 Chromosome analyses patients), second remission (2CR, one patient), and first were performed on bone marrow cells (24 and/or 48 h in relapse (1rel, one patient). Two patients were transplanted vitro culture with GTG (G-bands obtained by trypsin and with autologous bone marrow, and eight patients received stained with Giemsa)). In all patients a pericentric inversion allogeneic grafts. Seven donor/recipient pairs were matched 16 could be demonstrated prior to transplant. at the HLA-A, B, C and DR loci and were nonreactive in mixed lymphocyte culture (MLC), and one patient (UPN 936) received a graft from an antigen-mismatched unrelated donor (one mismatch of six). All recipients of allogeneic
Isolation of RNA and cDNA synthesis and reverse transplantation except one received grafts from family transcription donors. BM or blood samples were studied 1 month before transplantation and 1 to 64 months after transplant. The RNA was prepared from fresh or cyropreserved peripheral blood cells or BM buffy coat cells, Kasumi-1 and K562 median time to last follow-up for all patients was 6 months. Approval for this study was obtained from the Institutional cells provided negative controls for RT-PCR. Blood from a patient (UPN 799) with a CBF␤/MYH11 fusion transcript Review Board on Medical Ethics at the Essen University Hospital. All patients gave informed consent before was used as a positive control. RNA was extracted by the acid guanidium/phenol/chloroform method. 10 For each material was obtained.
PCR, cDNA was synthesized from 2 g of total RNA with 200 U Moloney murine leukemia virus (MoMuLV) reverse Conditioning regimens and GVHD prophylaxis transcriptase (Gibco-BRL, Gaithersburg, MD, USA) in PCR buffer (50 mmol/l KCl, 10 mmol/l Tris-HCl pH 8.3, The conditioning regimen consisted in five patients of cyclophosphamide (60 mg/kg/day × 2) and fractioned total 1.5 mmol/l MgCl 2 , 0.001% gelatin (Perkin Elmer Cetus, Weiterstadt, Germany), using random hexamers (10 body irradiation (TBI) delivered from a cobalt source in four daily fractions of 2.5 Gy to a total dose of 10 Gy. mmol/l) (Boehringer, Mannheim, Germany), deoxynucleotide triphosphates 8dNTP; 1 mmol/l each), 20 U RNAsin Four patients received busulfan (4 mg/kg/day for 4 days) followed by cyclophosphamide (60 mg/kg/day × 2), and at a final volume of 20 l at 37°C for 1 h. UPN = unique patient number; R = recipient; D = donor; GVHD = graft-versus-host disease; 1CR/2CR, first/second remission; PBPCT = peripheral blood progenitor cell transplantation; BMT = bone marrow transplantation; MTX = methotrexate; CsA = cyclosporin A; TBI = total body irradiation; CY = cyclophosphamide; Bu = busulfan; Th = thiotepa; bro = brother; id = identical; unr = unrelated; si = sister; lim = limited; ext = extensive; DFS = disease-free survivor. For PCR amplification we used specific primers designed to flank repeat units of the following human minisatellite denaturation step of 3 min at 95°C, followed by 25 cycles of denaturation at 95°C for 30 s and annealing at 57°C for regions: D1S80 as previously described. 14 These loci were selected because they exhibit a high degree of polymor-30 s.
The C1M1 and C2M7 product of type A was amplified phism and are suitable for PCR amplification. PCR of minisatellite region D1S80: PCR reaction was as a band at 420 bp (C1M1) or 65 bp (C2M7) on a 4% agarose gel stained with ethidium bromide (data of C1M1 performed in a volume of 50 l with 10 ng of blood DNA template using a commercially purchased PCR amplifiproduct are not shown).
cation kit from Perkin Elmer. DNA was denatured for 4 min at 95°C, followed by 29 cycles at 95°C (15 s), 66°C RNA quality control (15 s), and 72°C (40 s). After the last cycle, the samples were held at 72°C for 10 min and finally at 4°C. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger RNA or ␤-actin mRNA were coamplified as a control in all RT-PCR. 4, 11 From all samples, the cDNA was PCR primers for analysis of Y chromosome-specific divided into two tubes. One tube was used as an RNA qualnucleotide sequences ity control containing a final volume of 25 l with 1 × PCR Chimerism analysis of male patients with female donor buffer with 50 mmol/l KCl, 10 mmol/l Tris-HCl pH 8.3, were perfomed by PCR amplification of Y-chromosome-1.5 mmol/l MgCl 2 , 0.001% gelatin (Perkin Elmer Cetus), specific nucleotide sequences as previously described. 15 A 0.2 mmol/l each of NTP, 2.5 U Taq polymerase (Perkin 150 bp sequence was amplified with the primers H3 and Elmer Cetus) and 12 pmol/l of each GAPDH specific pri-H4. 15 The ZP3 gene located on chromosome 7 was used mers or ␤-actin specific primers, which results in a positive as a control gene with the primers ZP1 and ZP2. 16 200 bp band or 420 bp band from all human RNA, and Briefly, reagents were transferred to 0.5 ml PCR-reaction therefore, controls for the quality of RNA and successful tubes. The reaction volume was 25 l and contained 50 PCR amplification. 4, 11 mmol/l KCl, 10 mmol/l Tris pH 8.3 at 20°C, 0.001% gelatin, 0.2 mmol/l of each dNTP, 20 pmol of each primer, 2 U of AmpliTaq DNA polymerase (Perkin Elmer Cetus), 1.5 PCR controls mmol/l MgCl 2 and 250 ng of blood DNA template. DNA Elaborate measures were taken to minimize contamination was denatured for 4 min at 94°C, followed by 35 cycles at following the recommendations of Kwok and Higuchi. 12 94°C (1 min), 65°C (1 min), and 72°C (2 min). RNA and DNA extractions were performed at separated work places using dedicated PCR reagents and pipettes. All
Analysis of PCR products PCR products were kept in separate laboratory rooms from patients samples, RNA and PCR reagents.
Amplified DNA of minisatellite region D1S80 was run on Blank controls were included in all RNA extraction proa high resolution gel according to the manufacturer's cedures as negative controls to assess quality and crossinstructions (Gene Amp Detection Gel; Perkin Elmer contamination between samples. Cells from Kasumi-1 and Cetus). Following electrophoresis, the gels were silver K562 cell lines were used as a negative control, and cells stained and thereafter photographed. of a CBF␤/MYH11-positive patient were included as a positive control.
Sensitivity of PCR assays For a patient sample to be considered negative for amplification of the CBF␤/MYH11 fusion transcript, it had to:
Chimerism studies: Using the minisatellite primer D1S80 a sensitivity of 1:10 3 was obtained as previously pub-(1) be amplified in two independent experiments using 2.0 lished.
14 The sensitivity of the Y-chromosome-specific PCR was 1:10 5 .
15
MRD studies: To assess the sensitivity of the RT-PCR amplification of the CBF␤/MYH11 fusion transcripts, 1 g of total RNA isolated from BM of patient UPN 936 at presentation prior to transplantation was serially diluted in RNA isolated from mononuclear peripheral blood cells of a healthy donor. The resulting cDNA was then submitted to 35 cycles of amplification with primers C1 and M1, followed by 25 cycles of amplification with nested primers C2 and M7.
Results

Detection of CBF␤/MYH11 fusion transcript in patients with inv(16) AML before transplant
In all 10 patients, diagnostic or relapse BM or blood samples obtained before allogeneic or autologous transplant were available for amplification by RT-PCR. Eight patients were in first remission, one was in second remission (UPN 876) and another was in first relapse (UPN 936) ( Figure 1 ). In all patients analyzed prior to transplant, a 65 bp nested RT-PCR product consistent with a type A CBF␤/MYH11 fusion transcript could be detected in bone marrow or blood samples. In patient UPN 936 a 420 bp RT-PCR product from the first PCR step consistent with type A analyses. These three patients remained in complete remission according to morphologic and cytogenetic bone marrow analyses.
One patient (UPN 936) was found to be positive for CBF␤/MYH11 in blood and cerebrospinal fluid prior to PBPCT, but had a negative PCR assay 1 and 3 months post-transplant in BM, blood and cerebrospinal fluid. This patient achieved a complete remission after PBPCT but developed a severe infection and died 3 months post-allogeneic PBPCT (Figures 3 and 4) .
Two patients (UPN 469 and 554) could be monitored 64 and 50 months after allogeneic BMT for CBF␤/MYH11 fusion transcripts. Both patients were found to be negative BMT from these two patients remained negative for the fusion transcript. Morphological and cytogenetic BM analysis revealed a remaining complete remission for both patients.
Chimerism in AML-M4Eo patient
The chimerism status was studied in all eight AML-M4Eo patients using peripheral blood samples. In three male patients with a female donor the chimerism analysis was performed by PCR amplification of Y-chromosome-specific sequences. In five patients PCR amplification of the minisa- One month post-transplant chimerism analyses were performed in six of eight patients. In none of the six patients studied was a mixed chimerism detected. fusion transcript 3 months post-transplant (Figure 1 ). Two of these eight patients (UPN 799, 856) showed a positive Three months post-transplant chimerism analyses were performed in all eight patients who received an allogeneic PCR assay, whereas the remaining six patients were CBF␤/MYH11 negative. One patient of the two patients transplant. All patients showed a complete chimerism when analyzed at that time. Patient UPN 799 revealed a mixed who was positive for CBF␤/MYH11 (UPN 799) 3 months post-transplant remained PCR-positive for the fusion tranchimerism status 6 months post-transplant demonstrated by performing a PCR of Y-chromosome-specific gene scripts when tested 6 months post-transplant. This patient was transplanted with allogeneic PBPCs. He relapsed 7
sequences. An MRD analysis performed at the same time showed him to be positive for CBF␤/MYH11. This patient months post-transplant by developing an extramedullary tumor. A histological examination of a biopsy sample of developed an extramedullary relapse of the AML-M4Eo 7 months post-transplant. the extramedullary tumor showed a relapse of the AMLM4Eo leukemia. After surgery was done and chemotherapy
The remaining four patients who were tested to have a complete chimerism 1 month or 3 months post-transplant, was given this patient achieved a transient remission again, but remained PCR-positive for CBF␤/MYH11 fusion tranremained with complete chimerism when analyzed at a later time period, including two patients who were analyzed 64 script when monitored up to 16 months post-transplant. This patient died 18 months post-PBPCT.
and 50 months post-transplant. Another patient (UPN 856) was PCR positive for CBF␤/MYH11 in a BM sample, but not in a simultaneously examined blood sample, suggesting that analyses from BM samples are more sensitive than blood samples. A BM sample obtained 6 months post-BMT from the same patient was Sensitivity of the RT-PCR for the detection of the found to be negative by PCR. This patient died 12 months CBF␤/MYH11 fusion transcript post-BMT from a severe CMV infection.
Sequential PCR tests were performed 1, 3, 6, and 12 Using an amount of 1 g RNA in all RT-PCR, the sensitivity analysis showed that the RT-PCR technique could months post-transplant in three patients (UPN 890, 876, 868). All three patients were found to be negative for the reliably detect 100 pg of rearranged RNA in 1 g of RNA of normal cells (data not shown). CBF␤/MYH11 fusion transcript in these sequential PCR
Discussion
results were found in four of five patients, using a PCR assay with a low sensitivity of 10
Ϫ4
. In three other reports, 11 patients with inv(16) were monitored for CBF␤/MYH11 fusion transcripts after CBF␤/MYH11 transcripts are found in the great majority of inv(16) AML and also in approximately 10% of patients achieving a complete remission by chemotherapy. Claxton et al 5 studied three AML patients with inv(16) who had with AML-M4.
14 Four types (A-D) of fusion transcripts for this gene have been described, representing different hematological remissions; one patient was RT-PCR-positive with morphologic remission at day 21 after therapy for breakpoints within the MYH11 gene, with type A being predominant. [4] [5] [6] [7] [8] relapse, and two patients in remission for more than 1 year were RT-PCR-negative. Poirel et al 6 reported RT-PCR posThe common A-type fusion transcript was found in all AML patients with inv(16) studied here prior to BMT or itivity in three AML/inv(16) patients studied at 1, 3 and 6 months after diagnosis. Herbert et al 4 studied five AML-PBPCT.
In the present report, we provide the largest series to date M4Eo patients with inv(16): four patients in remission for 4-22 months had detectable CBF␤/MYH11 fusion tranof leukemia patients with inv(16) studied for the evidence of the CBF␤/MYH11 fusion transcript following allogeneic scripts while one patient in complete remission for 60 months was RT-PCR negative. BMT. Before this series, analyses of the CBF␤/MYH11 were reported in only three cases following allogeneic
The different results which were reported in several studies above might be caused primarily by using PCR tech-BMT. In one of these three cases, 22 months post-allogeneic BMT, CBF␤/MYH11 fusion transcripts were niques with different sensitivities and different RNA amounts. According to Jurlander et al 18 the sensitivity of a detected only in bone marrow, but not in peripheral blood. In two cases CBF␤/MYH11 could not be detected by RT-RT-PCR assay is influenced by the amount of RNA which is used in the PCR. In our study we therefore used 2 g PCR when analyzed 3 months post-transplant. RT-PCR was performed in one case from bone marrow, and in the other RNA in all PCR to ensure a sensitivy of 10 Ϫ5 in all PCRs. With regard to monitoring minimal residual disease, case only from peripheral blood.
7,8
The results presented in this study demonstrate that the there might be some similarities found between the detection of CBF␤/MYH11 fusion transcripts and AML1/ETO CBF␤/MYH11 fusion trancript was no longer detectable in six of the seven patients who were in remission after allotranscripts in patients with AML. As described above for the detection of CBF␤/MYH11 transcripts in patients with geneic BMT or PBPCT. Two of these patients in remission were monitored up to 50 and 64 months post-BMT.
inv(16), the AML1/ETO transcript is also detectable in patients in remission after chemotherapy. 19-24 Therefore, One patient who remained in complete remission after allogeneic BMT, was PCR positive 3 months post-BMT in studies after chemotherapy or autologous BMT on CBF␤/MYH11 or AML1/ETO may not be very predictive a BM sample, but not in a simultaneously examined blood sample, suggesting that analyses from BM samples are in regard to leukemic relapse when a persistence of these fusion transcripts was reported. In these cases, a reliable more sensitive than blood samples. This observation was also described by Tobal et al. 7 quantitative PCR assay may be helpful. However, the reliability of semiquantitative competitive PCR assays as Another patient with a positive PCR test 3 months post-PBPCT, remained PCR positive for the CBF␤/MYH11 developed by Evans et al 17 has not yet been sufficiently determined and needs to be proven by further studies from fusion transcript when tested 6 months post-PBPCT. This patient suffered from leukemic relapse 7 months post-transother investigators. Patients in remission after allogeneic BMT or PBPCT plant.
Before transplant, in all nine patients who were in comdid not show a persistence of CBF␤/MYH11 fusion transcripts in this report. A negative PCR assay for AML1/ETO plete remission (eight patients in 1CR, one patient in 2CR), the CBF␤/MYH11 transcript was detectable. In patient is also found in many patients in remission after allogeneic BMT or PBPCT studied for AML1/ETO. 19 This shows that UPN 936, who was transplanted in relapse, the fusion transcript was not only detectable in blood and bone marrow, patients who were positive for CBF␤/MYH11 prior to allogeneic BMT or PBPCT, seem to be able to obtain a molecubut also in a cerebrospinal fluid sample.
Two patients who received an autologous BMT were lar remission after transplant. Therefore, it may confirm on a molecular level the superior antileukemic effect of an monitored for CBF␤/MYH11 transcripts 3 months after transplant. The CBF␤/MYH11 transcript was detected in allogeneic BMT or PBPCT towards that of chemotherapy and autologous BMT in patients with AML. both patients. Both patients subsequently relapsed 3 and 23 months post-autologous BMT.
Similarities between AML1/ETO and CBF␤/MYH11 are not only seen in their use as MRD markers. Moreover, the Studies of the detection of CBF␤/MYH11 transcripts in patients who were in remission after chemotherapy or auto-CBF␤ protein and the AML-1 protein are able to interact with each other. So, CBF␤ is a human homologue of the logous transplantation, show a persistence of the fusion transcript in a number of patients. [4] [5] [6] [7] Using a competitive ␤-subunit of the heterodimeric polyomavirus enhancer core binding factor protein, PEBP2␣␤, a murine transcription PCR assay, Evans et al 17 found in five of eight patients positive PCR results for CBF␤/MYH11 transcripts after factor, whereas the protein AML-1 has been identified and fulfills the requirements for the DNA-binding ␣-subunit. chemotherapy alone. Costello et al 8 reported PCR positivity for CBF␤/MYH11 fusion trancripts in five of six patients Therefore, AML-1 directly interacts with CBF␤. It has been shown that in the majority of cases, the chimeric protein within 2 months after the induction therapy, whereas after autologous transplantation with PBPCs negative PCR CBF␤/MYH11 retains its ability to interact strongly with 
